don t be mellow when an infant is yellow deciphering
play

Dont be Mellow When an Infant is Yellow: Deciphering Cholestasis - PowerPoint PPT Presentation

Dont be Mellow When an Infant is Yellow: Deciphering Cholestasis Catherine J. Goodhue, MN, RN, CPNP-PC Research Program Manager Division of Pediatric Surgery Disclosure Research Coordinator of an NIH-funded U01 Grant entitled:


  1. Don’t be Mellow When an Infant is Yellow: Deciphering Cholestasis Catherine J. Goodhue, MN, RN, CPNP-PC Research Program Manager Division of Pediatric Surgery

  2. Disclosure • Research Coordinator of an NIH-funded U01 Grant entitled: Establishment of CHLA’s ChiLDREN (Childhood Liver Disease Research and Education Network) Clinical Center

  3. Objectives At the end of this presentation, the participant will be able to: 1. Describe at least 3 functions of the liver 2. Identify the most critical differential diagnoses for cholestatic jaundice in the newborn period 3. Discuss the long-term treatment for an infant with cholestatic jaundice

  4. Functions of the Liver • Regulates distribution and metabolism of all nutrients from GI tract • Bile production • Detoxification • Assists immune system – filtering bacteria and other “bugs” • Assists in maintaining normal blood circulation

  5. What is Bilirubin? • Formed from degradation of hemoglobin – Newborns produce twice as much bilirubin as adults • Heme converted to biliverdin heme oxygenase in RES • Biliverdin reduced to unconjugated bilirubin and bound to albumin and sent to liver • In liver, unconjugated bilirubin is conjugated with glucuronic acid • Most goes into bile and excreted into small intestine

  6. Physiologic Jaundice of Newborns • Phase one – Term infants – lasts up to 5 days with rapid rise of serum bilirubin up to 12 mg/dL – Preterm infants – lasts up to 7 days with rapid rise of serum bilirubin up to 15 mg/dL • Phase two – bilirubin levels decline ~ 2mg/dL over 2 weeks – Preterm infants – can last more than 1 month – With exclusive breast feedings, can last more than 1 month

  7. Pathologic Jaundice Neonatal Jaundice Unconjugated hyperbilirubinemia Conjugated hyperbilirubinemia Pathologic Physiologic jaundice Hepatic Post-hepatic of neonates Hemolytic Non-hemolytic 1 in 2500 live births Intrinsic Extrinsic

  8. All jaundiced infants should have a fractionated bilirubin at 2 weeks of age • Measure both conjugated and unconjugated bilirubin - conjugated should < 30% total bilirubin

  9. Defining Cholestasis • Physiologic definition : measurable decrease in bile flow • Pathological definition : histological presences of bile pigment in hepatocytes and bile ducts • Clinical definition : accumulation in blood and extrahepatic tissues of substances normally excreted in bile From Suchy, Sokol, Balistreri. Liver Disease in Children, 2001

  10. Signs and Symptoms of Cholestasis • Jaundice • Icterus • Pruritus • Dark urine • Elevated bilirubin level • Elevated liver enzymes

  11. Case Study: Sandra

  12. Differential Diagnosis of Cholestasis Neonatal hepatitis • Cholestatic syndromes • Idiopathic – PFIC – Viral – BRIC – Bacterial – Metabolic disorders • Bile duct obstruction • Alpha 1 antitrypsin deficiency – Cholangiopathies – CF – • Biliary atresia Bile acid synthesis defects – • Alagille’s Toxic • • Choledochal cysts Drugs – Other – TPN – • Cholelithiasis Miscellaneous • • Tumors/masses Shock/hypoperfusion – ECMO – From Suchy et al., 2001

  13. Evaluation of Cholestasis Timely referral to Pediatric Detailed H & P • • Hepatologist/GI and/or Pregnancy history – Pediatric Surgeon Family history – Abdominal ultrasound Neonatal course – – Serologies for infections Extrahepatic anomalies – – Sweat chloride Stool color – – Alpha 1 antitrypsin level and Laboratory testing – • phenotype Fractionated bilirubin – Metabolic screen – AST , ALT , Alk phos – Serum iron and ferritin – Liver function tests – Genetic testing – CBC – X-rays – Bacterial cultures – HIDA scan – Liver biopsy – From Suchy et al., 2001 IOC –

  14. More Common Causes of Conjugated Hyperbilirubinemia • TPN-cholestasis • Idiopathic neonatal hepatitis • Alpha-1-antitrypsin deficiency • Bile acid synthesis defects • Progressive familial intrahepatic cholestasis • Alagille ’ s syndrome • Biliary atresia

  15. TPN-associated Cholestasis • Short gut/prematurity • TPN developed by Ravdin, Roads, Dudrick 1960s • Progressive hyperbilirubinemia assoc with prolonged TPN use • Treatment Reversible in most instances with – discontinuation of TPN Cycling of TPN – Homocysteine – Parenteral Omega-3 fatty acids –

  16. Idiopathic Neonatal Hepatitis • Unresolved conjugated hyperbilirubinemia • “Giant cell hepatitis” • Diagnosis of exclusion after metabolic, infectious, genetic, or obstructive causes of cholestasis • Up to 20% progressive, familial and worse prognosis

  17. Idiopathic Neonatal Hepatitis Cont • 40% of cholestatic infants have INH • Male: female 2:1 • Present with jaundice and acholic stools • Recovery rates range from 60-80% for sporadic cases; familial 20-40% recovery rate

  18. Alpha 1 Antitrypsin Deficiency • Inborn error of metabolism mutant α1-AT accumulates in the endoplasmic reticulum – leaving trypsin-mediated proteolysis uninhibited in connective tissues • 1 in 2,000 live births in U.S. • Homozygous α1-AT deficiency associated with pulmonary emphysema, chronic liver disease, and hepatocellular carcinoma

  19. A1AT Continued • Diagnosis • Treatment – Prolonged jaundice – Supportive management of liver dysfunction – Neonatal hepatitis syndrome – Avoidance of cigarette smoking – Mild elevation AST/ALT in toddlers – Liver transplant if liver failure – Portal hypertension in child/teen – Severe liver dysfunction in child/teen – HSP

  20. Bile Acid Synthesis Defects • 1 in 100,000 • Enzyme dysfunction at various steps of bile acid biosynthesis accumulation of atypical hepatotoxic bile acid precursors. – 6 identified – • Diagnosis: mass spectrometry of urine • Treatment: cholic acid therapy downregulation of intrinsic bile acid synthesis – reduction in the accumulation of toxic bile acid precursors –

  21. Progressive Familial Intrahepatic Cholestasis • Rare inherited diseases resulting from defects in bile synthesis and secretion • Estimated prevalence is 1 in 70,000 • Clinical manifestations : – Cholestasis may progress from intermittent to persistent – Pruritus may/may not be associated with jaundice; absence of jaundice may lead to delay in diagnosis – Malabsorption of fat soluble vitamins is common

  22. Alagille Syndrome • Cholestasis- paucity of intrahepatic bile ducts, cardiac defects, characteristic facies, eye findings, renal anomalies, and butterfly vertebrae • Autosomal dominant • 1 in 100,000 live births • Mutations in JAG1 (Notch signaling) • Prognosis dependent on severity of CV & hepatic disease • 15% progress to end-stage liver failure -> transplantation

  23. Biliary Atresia • Progressive obliterative idiopathic cholangiopathy – Most common cause of chronic cholestasis in infants – Jaundice & acholic stools • 1:8,000-1:12,000 live births • F>M • Seasonal clustering • Lethal if untreated

  24. Diagnosis of Biliary Atresia • Conjugated hyperbilirubinemia • Mildly elevated ALT , AST with normal AST:ALT ratio • Elevated GGT • Ultrasound • HIDA scan • Liver Biopsy

  25. Ultrasound Findings - BA • Absent or small gallbladder • Cyst at the porta hepatis • Increased echogenicity • Nondilated intrahepatic ducts and nonvisualized CBD

  26. HIDA Scan • Hepatic Technetium 99 Tc m c iminodiacetic acid • Non-excretion into small intestine

  27. Liver Biopsy - BA Portal inflammation Bile plugs Ductular proliferation

  28. Intraoperative Cholangiogram

  29. Kasai Procedure Kasai and Shujitsu, 1959 Kasai, M., S. Kimura, et al. J Ped Surg, 1968 Excision of fibrotic mass in hilum of liver Drainage - Roux-en-Y portoenterostomy

  30. Dissection of biliary remnant

  31. Bile Pooling at Portal Plate

  32. Timing of Diagnosis/Treatment is Key! From Ohi R. Biliary Atresia: A Surgical Perspective. Clin Liver Disease 2000

  33. Post-operative Management • Antibiotic cholangitis prophylaxis • Post-operative steroids unproven • Analgesics • Oral bile acid therapy • Vitamin supplements/monitor vitamin levels • Possible anti-pruritus therapy • Monitor bilirubin/liver function tests • Other therapies – Probiotics – unproven – Herbal remedies – unproven – Omega 3 supplements - unproven

  34. Fat Soluble Vitamins • Vitamin A – Integral for vision, immune function and growth • Vitamin D – Integral for bone health, immune function, growth, and prevention of chronic disease • Vitamin E – Powerful antioxidant, prevents damage to cells • Vitamin K – Component of many proteins in body including those involved in clotting and bone formation

  35. Primary Care Management • Ensure regular follow-up with hepatologist/GI • Follow-up with surgeon as directed • Keep childhood vaccines up to date • Annual flu shot • Follow growth and nutritional status – Anthropometric measurements – Possible dietary consults if not gaining adequate weight – Avoid obesity • Avoid unnecessary medications and remedies (OTC and rx)

  36. Family Education • Contact MD if: – Unexplained fever – Recurrent/worsening jaundice – Swollen belly or extremities – Abnormal bleeding – Can’t or won’t eat – Pale stools

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend